New Strategies for the Treatment of Early Stages of Hodgkin's Lymphoma

Hematology/Oncology Clinics of North America

Volumn 21, Issue 5, 2007, Pages 871-880

  Macdonald, David A ^a   Connors, Joseph M ^b,c  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; METHOTREXATE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; HODGKIN DISEASE; HUMAN; INTERMETHOD COMPARISON; LAPAROTOMY; METASTASIS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SECOND CANCER; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; HODGKIN DISEASE; HUMANS; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT;

EID: 34748815674     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.06.014     Document Type: Review

References (34)

1. Diehl V., Mauch P.M., and Harris N.L. Hodgkin's disease. In: DeVita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles and practice of oncology. 6th edition (2001), Lippincott Williams & Wilkins, Philadelphia 2339-2387
2. Peters M.A. A study of survivals in Hodgkin's disease treated radiologically. AJR Am J Roentgenol 63 (1950) 299-311
3. Kaplan H. The radical radiotherapy of regionally localized Hodgkin's disease. Radiology 78 (1962) 553-561
4. Sieber M, Franklin J, Tesch H. Two cycles of ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin's disease: results of the German Hodgkin's Lymphoma Study Group (GHSG) Trial HD7. Paper presented at the American Society of Hematology, Philadelphia, December 8-12, 2002.
5. Hoppe R.T. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol 8 Suppl 1 (1997) 115-118
6. DeVita V.T., and Serpick A.A. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Proc Am Assoc Cancer Res 8 (1967) 13
7. Lister T.A., Crowther D., Sutcliffe S.B., et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. [published erratum appears in J Clin Oncol 1990 Sep;8(9):1602]. J Clin Oncol 7 11 (1989) 1630-1636
8. Carde P., Hagenbeek A., Hayat M., et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 11 11 (1993) 2258-2272
9. Connors J.M. State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol 23 26 (2005) 6400-6408
10. Diehl V., Thomas R.K., and Re D. Part II: Hodgkin's lymphoma-diagnosis and treatment. Lancet Oncol 5 1 (2004) 19-26
11. Vijayakumar S., and Myrianthopoulos L. An updated dose-response analysis in Hodgkin's disease. Radiother Oncol 24 1 (1992) 1-13
12. Duhmke E., Diehl V., Loeffler M., et al. Randomized trial with early-stage Hodgkin's disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. Int J Radiat Oncol Biol Phys 36 2 (1996) 305-310
13. Press O.W., LeBlanc M., Lichter A.S., et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 19 22 (2001) 4238-4244
14. Specht L., Gray R.G., Clarke M.J., et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol 16 3 (1998) 830-843
15. Bonadonna G., Bonfante V., Viviani S., et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 22 14 (2004) 2835-2841
16. Noordijk E.M., Carde P., Dupouy N., et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials. J Clin Oncol 24 19 (2006) 3128-3135
17. Radford J., Williams M., and Hancock B. Minimal initial chemotherapy plus involved field radiotherapy (RT) versus mantle field RT for clinical stage I/IIA supradiaphragmatic Hodgkin's disease (HD). Results of the UK Lymphoma Group LY07 trial. Br J Cancer 91 Suppl 1 (2004) S1-S2 [abstract CT1]
18. Horning S.J., Hoppe R.T., Mason J., et al. Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. J Clin Oncol 15 5 (1997) 1736-1744
19. Hagenbeek A., Eghbali H., Fermé C., et al. Three cycles of MOPP/ABV hybrid and involved-field irradiation is more effective than subtotal nodal irradiation in favorable supradiaphragmatic clinical stages I-II Hodgkin's disease: preliminary results of the EORTC-GELA H8-F randomized trial in 543 patients. Blood 96 (2000) 575a
20. Diehl V, Brillant C, Engert A, et al. HD10: investigating reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma. Interim analysis of a randomized trial of the German Hodgkin Study Group (GHSG). J Clin Oncol (Meeting Abstracts) 2005;23(Suppl 16):6506.
21. Noordijk EM, Thomas J, Ferme C, et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL). J Clin Oncol (Meeting Abstracts) 2005;23(Suppl 16):6505.
22. Canellos G.P., Anderson J.R., Propert K.J., et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327 21 (1992) 1478-1484
23. Diehl V., Brillant C., Engert A., et al. Recent interim analysis of the HD11 trial of the GHSG: intensification of chemotherapy and reduction of radiation dose in early unfavorable stage Hodgkin's lymphoma. Blood 106 11 (2005) [abstract #816]
24. Diehl V., Stein H., Hummel M., et al. Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology: Am Soc Hematol Educ Program Book (2003) 225-247
25. Duhmke E., Connors J.M., Pavlovsky S., et al. Treatment of clinical stage I-II Hodgkin's disease. In: Mauch P.M., Armitage J.O., Diehl V., et al. (Eds). Hodgkin's disease (1999), Lippincott Williams & Wilkins, Philadelphia 435
26. Rueda Dominguez A., Marquez A., Guma J., et al. Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Ann Oncol 15 12 (2004) 1798-1804
27. Henry-Amar M., Meerwaldt J.H., and Carde P. The EORTC treatment strategy in Hodgkin's lymphoma: a 4-decade experience. Leuk Lymphoma 42 Suppl 2 (2001) 54
28. Nachman J.B., Sposto R., Herzog P., et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 20 18 (2002) 3765-3771
29. Laskar S., Gupta T., Vimal S., et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?. J Clin Oncol 22 1 (2004) 62-68
30. Straus D.J., Portlock C.S., Qin J., et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 104 12 (2004) 3483-3489
31. Meyer R.M., Gospodarowicz M.K., Connors J.M., et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23 21 (2005) 4634-4642
32. de Wit M., Bohuslavizki K.H., Buchert R., et al. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 12 1 (2001) 29-37
33. Rigacci L., Castagnoli A., Dini C., et al. 18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results. Oncol Rep 14 5 (2005) 1209-1214
34. Kostakoglu L., Goldsmith S.J., Leonard J.P., et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 107 11 (2006) 2678-2687